by Eric Christianson | Oct 25, 2026 | Renal, Urology, and Electrolytes Medication and Disease State Clinical Pearls
When we think about medications that cause hyperkalemia (elevated potassium), ACE inhibitors, ARBs, and spironolactone usually come to mind. However, several other medications can increase potassium levels and are easy to overlook in clinical practice. Here are three...
by Eric Christianson | Aug 12, 2026 | Renal, Urology, and Electrolytes Medication and Disease State Clinical Pearls
Finerenone (Kerendia) is a relatively newer medication for the management of chronic kidney disease (CKD) in patients with type 2 diabetes and heart failure with preserved ejection fraction. In addition to these indications, there was a recent study that showed...
by Eric Christianson | Feb 5, 2025 | Cardiovascular Medication and Disease State Clinical Pearls
This video is part of a three-part series covering new literature that could influence clinical practice. Finerenone has been studied in the setting of HFpEF and I review this topic. More specifically, in this video, I discuss the background of why finerenone may be...
by Eric Christianson | Jan 8, 2023 | Clinical Guideline Updates For Pharmacists
The ADA has released its 2023 guidelines. There are a significant number of impacts on medication therapy, and in this post I will outline my most important takeaways. I was also recently catching up with my friend and fellow pharmacist, Derek Borkowski who is the...
by Eric Christianson | Jan 12, 2022 | Clinical Guideline Updates For Pharmacists
The American Diabetes Association released their 2022 Diabetes Guidelines update. While I wouldn’t call the changes earth-shattering, there are some items in relation to pharmacotherapy that I feel are really important to note. The patient population that I work...
